Ani Pharmaceuticals (ANIP) Retained Earnings (2016 - 2025)
Ani Pharmaceuticals (ANIP) has disclosed Retained Earnings for 16 consecutive years, with $1.0 million as the latest value for Q4 2025.
- Quarterly Retained Earnings rose 101.03% to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, up 101.03% year-over-year, with the annual reading at $1.0 million for FY2025, 101.03% up from the prior year.
- Retained Earnings hit $1.0 million in Q4 2025 for Ani Pharmaceuticals, up from -$50.6 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $13.7 million in Q2 2023 to a low of -$100.3 million in Q4 2024.
- Historically, Retained Earnings has averaged -$45.9 million across 5 years, with a median of -$56.5 million in 2024.
- Biggest five-year swings in Retained Earnings: plummeted 1257.31% in 2022 and later skyrocketed 152.78% in 2023.
- Year by year, Retained Earnings stood at -$47.8 million in 2021, then tumbled by 103.68% to -$97.3 million in 2022, then grew by 17.63% to -$80.1 million in 2023, then decreased by 25.14% to -$100.3 million in 2024, then surged by 101.03% to $1.0 million in 2025.
- Business Quant data shows Retained Earnings for ANIP at $1.0 million in Q4 2025, -$50.6 million in Q3 2025, and -$76.9 million in Q2 2025.